Purificacao A, Silva-Mendonca S, Cruz L, Sacramento C, Temerozo J, Fintelman-Rodrigues N
ACS Omega. 2024; 9(10):11418-11430.
PMID: 38496952
PMC: 10938441.
DOI: 10.1021/acsomega.3c07845.
Su P, Yang C, Wang X
BMC Infect Dis. 2024; 24(1):44.
PMID: 38172735
PMC: 10765622.
DOI: 10.1186/s12879-023-08828-2.
Homma T, Okamoto M, Koharazawa R, Hayakawa M, Fushimi T, Tode C
ACS Omega. 2023; 8(45):42248-42263.
PMID: 38024673
PMC: 10652723.
DOI: 10.1021/acsomega.3c04175.
Liu H, Chen J, Shao W, Yan S, Ding S
Clin Epidemiol. 2023; 15:1041-1053.
PMID: 37933389
PMC: 10625770.
DOI: 10.2147/CLEP.S422386.
Chen S, Zhang C, Chen D, Dong L, Chang T, Tang Z
Front Immunol. 2023; 14:1200289.
PMID: 37483597
PMC: 10358730.
DOI: 10.3389/fimmu.2023.1200289.
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.
Bekheit M, Panda S, Girgis A
Eur J Med Chem. 2023; 252:115292.
PMID: 36965227
PMC: 10023213.
DOI: 10.1016/j.ejmech.2023.115292.
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19.
Cheng S, Wang P, Chang C, Wang H, Wang C, Chiu K
Drug Des Devel Ther. 2023; 17:87-92.
PMID: 36698540
PMC: 9869894.
DOI: 10.2147/DDDT.S392708.
Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase.
Wang Z, Yang L, Song X
Front Immunol. 2022; 13:1015355.
PMID: 36561747
PMC: 9763260.
DOI: 10.3389/fimmu.2022.1015355.
Antiviral Disaccharide Lead Compounds against SARS-CoV-2 through Computer-Aided High-Throughput Screen.
Li B, Zhang T, Li J, Yu M
Chembiochem. 2022; 23(24):e202200461.
PMID: 36265004
PMC: 9874536.
DOI: 10.1002/cbic.202200461.
COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.
Yi J, Miao J, Zuo Q, Owusu F, Dong Q, Lin P
Front Immunol. 2022; 13:978619.
PMID: 36091053
PMC: 9459044.
DOI: 10.3389/fimmu.2022.978619.
Analysis of potential risk factors associated with COVID-19 and hospitalization.
Alharbi A, Rabbani S, Halim Mohamed A, Almushayti B, Aldhwayan N, Almohaimeed A
Front Public Health. 2022; 10:921953.
PMID: 35991020
PMC: 9389402.
DOI: 10.3389/fpubh.2022.921953.
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.
Wong C, Au I, Cheng W, Man K, Lau K, Mak L
Aliment Pharmacol Ther. 2022; 56(1):121-130.
PMID: 35318694
PMC: 9111503.
DOI: 10.1111/apt.16894.
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.
Khamees A, Bani-Issa J, Al Zoubi M, Qasem T, AbuAlArjah M, Alawadin S
Pathogens. 2022; 11(2).
PMID: 35215217
PMC: 8876838.
DOI: 10.3390/pathogens11020275.
Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
Arikawa S, Fukuoka K, Nakamoto K, Kunitomo R, Matsuno Y, Shimazaki T
Clin Exp Nephrol. 2022; 26(5):476-485.
PMID: 35182277
PMC: 8856930.
DOI: 10.1007/s10157-021-02151-3.
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y
Ann Med. 2022; 54(1):516-523.
PMID: 35118917
PMC: 8820829.
DOI: 10.1080/07853890.2022.2034936.
Potential Molecular Mechanisms and Remdesivir Treatment for Acute Respiratory Syndrome Corona Virus 2 Infection/COVID 19 Through RNA Sequencing and Bioinformatics Analysis.
Prashanth G, Vastrad B, Vastrad C, Kotrashetti S
Bioinform Biol Insights. 2022; 15:11779322211067365.
PMID: 34992355
PMC: 8725226.
DOI: 10.1177/11779322211067365.
Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action.
Zenchenko A, Drenichev M, Ilicheva I, Mikhailov S
Mol Biol. 2021; 55(6):786-812.
PMID: 34955556
PMC: 8682041.
DOI: 10.1134/S0026893321040105.
Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic.
Poliseno M, Gallo C, Cibelli D, Minafra G, Bottalico I, Bruno S
Antibiotics (Basel). 2021; 10(12).
PMID: 34943688
PMC: 8698274.
DOI: 10.3390/antibiotics10121477.
Predicting novel drug candidates against Covid-19 using generative deep neural networks.
Amilpur S, Bhukya R
J Mol Graph Model. 2021; 110:108045.
PMID: 34688160
PMC: 8510991.
DOI: 10.1016/j.jmgm.2021.108045.
Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.
Tammam S, El Safy S, Ramadan S, Arjune S, Krakor E, Mathur S
J Control Release. 2021; 337:258-284.
PMID: 34293319
PMC: 8289726.
DOI: 10.1016/j.jconrel.2021.07.028.
